Author Archives: ev1

Scarred Hearts Can Be Mended With Novel Stem Cell Therapy, Study Finds

Posted on by

Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure.

In a trial of 25 heart-attack patients, 17 who got the stem cell treatment showed a 50 percent reduction in cardiac scar tissue compared with no improvement for the eight who received standard care. The results, from the first of three sets of clinical trials generally needed for regulatory approval, were published today in the medical journal Lancet.

“The findings in this paper are encouraging,” Deepak Srivastava, director of the San Francisco-based Gladstone Institute of Cardiovascular Disease, said in an interview. “There’s a dire need for new therapies for people with heart failure, it’s still the No. 1 cause of death in men and women.”

The study, by researchers from Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins University (43935MF) in Baltimore, tested the approach in patients who recently suffered a heart attack, with the goal that repairing the damage might help stave off failure. While patients getting the stem cells showed no more improvement in heart function than those who didn’t get the experimental therapy, the theory is that new tissue regenerated by the stem cells can strengthen the heart, said Eduardo Marban, the study’s lead author.

“What our trial was designed to do is to reverse the injury once it’s happened,” said Marban, director of Cedars- Sinai Heart Institute. “The quantitative outcome that we had in this paper is to shift patients from a high-risk group to a low- risk group.”

Minimally Invasive

The stem cells were implanted within five weeks after patients suffering heart attacks. Doctors removed heart tissue, about the size of half a raisin, using a minimally invasive procedure that involved a thin needle threaded through the veins. After cultivating the stem cells from the tissue, doctors reinserted them using a second minimally invasive procedure. Patients got 12.5 million cells to 25 million cells.

A year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart. One of patient’s side effects were possibly linked to the treatment, the study found.

While the main goal of the trial was to examine the safety of the procedure, the decrease in scar tissue in those treated merits a larger study that focuses on broader clinical outcomes, researchers said in the paper.

Heart Regeneration

“If we can regenerate the whole heart, then the patient would be completely normal,” Marban said. “We haven’t fulfilled that yet, but we’ve gotten rid of half of the injury, and that’s a good start.”

While the study resulted in patients having an increase in muscle mass and a shrinkage of scar size, the amount of blood flowing out of the heart, or the ejection fraction, wasn’t different between the control group and stem-cell therapy group. The measurement is important because poor blood flow deprives the body of oxygen and nutrients it needs to function properly, Srivastava said.

“The patients don’t have a functional benefit in this study,” said Srivastava, who wasn’t not involved in the trial.

The technology is being developed by closely held Capricor Inc., which will further test it in 200 patients for the second of three trials typically required for regulatory approval. Marban is a founder of the Los Angeles-based company and chairman of its scientific advisory board. His wife, Linda Marban, is also a founder and chief executive officer.

“We’d like to study patients who are much sicker and see if we can actually spare them early death, or the need for a heart transplant, or a device,” Eduardo Marban said.

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please enable JavaScript to view the comments powered by Disqus.

Read the rest here:
Scarred Hearts Can Be Mended With Novel Stem Cell Therapy, Study Finds

Dogs who got stem cell therapy are well

Posted on by

WALKER, Mich. (WOOD) - Dogs who received the first in-clinic stem cell therapy in West Michigan returned to the vets who treated them Monday morning.

Boris and Natasha returned to Kelley's Animal Clinic for their 60-day checkup after receiving stem cell treatment in December 2011.

Dr. James Kelley and his staff of vets removed fat tissue from the dogs and activated it with an enzyme before injecting it into their back legs.

This adult animal stem cell technology is different from the controversial embryonic stem cell therapy.

Kelley said both dogs are doing amazingly well and that the procedure has done more than just help their arthritis.

"We're finding that not only the joints are affected, the rest of the animal is affected as well," said Kelley. "The skin is better. The attitude in these dogs is much improved."

Kelley and his staff have done 16 stem cell treatments since the first on Boris and Natasha, and he said all the dogs are showing signs of improvement after a short period of time.

Read more:
Dogs who got stem cell therapy are well

Scarred Hearts Can Be Mended With Stem Cell Therapy

Posted on by

February 14, 2012, 3:17 PM EST

By Ryan Flinn

(Adds comment from researcher in 13th paragraph.)

Feb. 14 (Bloomberg) -- Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure.

In a trial of 25 heart-attack patients, 17 who got the stem cell treatment showed a 50 percent reduction in cardiac scar tissue compared with no improvement for the eight who received standard care. The results, from the first of three sets of clinical trials generally needed for regulatory approval, were published today in the medical journal Lancet.

“The findings in this paper are encouraging,” Deepak Srivastava, director of the San Francisco-based Gladstone Institute of Cardiovascular Disease, said in an interview. “There’s a dire need for new therapies for people with heart failure, it’s still the No. 1 cause of death in men and women.”

The study, by researchers from Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins University in Baltimore, tested the approach in patients who recently suffered a heart attack, with the goal that repairing the damage might help stave off failure. While patients getting the stem cells showed no more improvement in heart function than those who didn’t get the experimental therapy, the theory is that new tissue regenerated by the stem cells can strengthen the heart, said Eduardo Marban, the study’s lead author.

“What our trial was designed to do is to reverse the injury once it’s happened,” said Marban, director of Cedars- Sinai Heart Institute. “The quantitative outcome that we had in this paper is to shift patients from a high-risk group to a low- risk group.”

Minimally Invasive

The stem cells were implanted within five weeks after patients suffering heart attacks. Doctors removed heart tissue, about the size of half a raisin, using a minimally invasive procedure that involved a thin needle threaded through the veins. After cultivating the stem cells from the tissue, doctors reinserted them using a second minimally invasive procedure. Patients got 12.5 million cells to 25 million cells.

A year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart. One of patient’s side effects were possibly linked to the treatment, the study found.

While the main goal of the trial was to examine the safety of the procedure, the decrease in scar tissue in those treated merits a larger study that focuses on broader clinical outcomes, researchers said in the paper.

Heart Regeneration

“If we can regenerate the whole heart, then the patient would be completely normal,” Marban said. “We haven’t fulfilled that yet, but we’ve gotten rid of half of the injury, and that’s a good start.”

While the study resulted in patients having an increase in muscle mass and a shrinkage of scar size, the amount of blood flowing out of the heart, or the ejection fraction, wasn’t different between the control group and stem-cell therapy group. The measurement is important because poor blood flow deprives the body of oxygen and nutrients it needs to function properly, Srivastava said.

“The patients don’t have a functional benefit in this study,” said Srivastava, who wasn’t not involved in the trial.

The technology is being developed by closely held Capricor Inc., which will further test it in 200 patients for the second of three trials typically required for regulatory approval. Marban is a founder of the Los Angeles-based company and chairman of its scientific advisory board. His wife, Linda Marban, is also a founder and chief executive officer.

“We’d like to study patients who are much sicker and see if we can actually spare them early death, or the need for a heart transplant, or a device,” Eduardo Marban said.

--Editors: Angela Zimm, Andrew Pollack

#<184845.409373.2.1.99.7.25># -0- Feb/14/2012 17:13 GMT

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

More:
Scarred Hearts Can Be Mended With Stem Cell Therapy

Vet offers stem cell therapy for dogs

Posted on by

COLUMBIA, SC (WIS) - Cutting-edge arthritis treatment for our four-legged family members is now available in Columbia.

Banks Animal Hospital is the first in the area to offer in-house Stem Cell therapy. It uses your pets own body to heal itself.

Take 13-year-old Maggie, for example. The energetic pup has a limp that usually keeps her from jumping or going up stairs.

"Today when everybody's out there filming her little limp it's not as pronounced because she wants to please," said Maggie's owner, Beth Phibbs. "She's just a great dog."

But a great attitude wasn't enough to repair a bad case of cervical spine arthritis.

So Monday, Beth brought Maggie to Banks Animal Hospital for the Stem Cell therapy. Like many, Beth had never heard of Stem Cell work in animals. "Until Dr. Banks mentioned it to me I was like, beg your pardon?"

"There's no down side, no side effects because you're using your own cells," said Dr Ken Banks.

Banks and his staff first gather some of Maggie's blood and fat. Both are good places to find the repair cells they're after. Adult stem cells, not the controversial embryonic kind, are then separated and spun down.

"The repair system in Maggie's body has failed," said Jason Richardson of MediVet-America. "It's fallen asleep at the wheel, we're taking these repair cells, activating them so a chronic condition like osteo arthritis to Maggie will now be an acute illness."

This kind of treatment used to take days with material being shipped across the country, but now it can be done in hours.

"The ability to do it same day, convenience, the ability to do it in clinic saves a lot of money to the doctor which he can then pass on to the patient," said Richardson.

The treatment will still run you around $2,000, but Richardson says that's half of what the similar treatment use to cost.

When it's over, Maggie should be able to live out her life pain and drug free -- something Phibbs is looking forward to.

"I'm hoping in a couple of weeks she's gonna have a new lease on life," said Phibbs.

Copyright 2012 WIS. All rights reserved.

Continued here:
Vet offers stem cell therapy for dogs

Scarred Hearts Can Be Mended With Stem Cell Therapy, Study Shows

Posted on by

February 14, 2012, 3:17 PM EST

By Ryan Flinn

(Adds comment from researcher in 13th paragraph.)

Feb. 14 (Bloomberg) -- Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure.

In a trial of 25 heart-attack patients, 17 who got the stem cell treatment showed a 50 percent reduction in cardiac scar tissue compared with no improvement for the eight who received standard care. The results, from the first of three sets of clinical trials generally needed for regulatory approval, were published today in the medical journal Lancet.

“The findings in this paper are encouraging,” Deepak Srivastava, director of the San Francisco-based Gladstone Institute of Cardiovascular Disease, said in an interview. “There’s a dire need for new therapies for people with heart failure, it’s still the No. 1 cause of death in men and women.”

The study, by researchers from Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins University in Baltimore, tested the approach in patients who recently suffered a heart attack, with the goal that repairing the damage might help stave off failure. While patients getting the stem cells showed no more improvement in heart function than those who didn’t get the experimental therapy, the theory is that new tissue regenerated by the stem cells can strengthen the heart, said Eduardo Marban, the study’s lead author.

“What our trial was designed to do is to reverse the injury once it’s happened,” said Marban, director of Cedars- Sinai Heart Institute. “The quantitative outcome that we had in this paper is to shift patients from a high-risk group to a low- risk group.”

Minimally Invasive

The stem cells were implanted within five weeks after patients suffering heart attacks. Doctors removed heart tissue, about the size of half a raisin, using a minimally invasive procedure that involved a thin needle threaded through the veins. After cultivating the stem cells from the tissue, doctors reinserted them using a second minimally invasive procedure. Patients got 12.5 million cells to 25 million cells.

A year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart. One of patient’s side effects were possibly linked to the treatment, the study found.

While the main goal of the trial was to examine the safety of the procedure, the decrease in scar tissue in those treated merits a larger study that focuses on broader clinical outcomes, researchers said in the paper.

Heart Regeneration

“If we can regenerate the whole heart, then the patient would be completely normal,” Marban said. “We haven’t fulfilled that yet, but we’ve gotten rid of half of the injury, and that’s a good start.”

While the study resulted in patients having an increase in muscle mass and a shrinkage of scar size, the amount of blood flowing out of the heart, or the ejection fraction, wasn’t different between the control group and stem-cell therapy group. The measurement is important because poor blood flow deprives the body of oxygen and nutrients it needs to function properly, Srivastava said.

“The patients don’t have a functional benefit in this study,” said Srivastava, who wasn’t not involved in the trial.

The technology is being developed by closely held Capricor Inc., which will further test it in 200 patients for the second of three trials typically required for regulatory approval. Marban is a founder of the Los Angeles-based company and chairman of its scientific advisory board. His wife, Linda Marban, is also a founder and chief executive officer.

“We’d like to study patients who are much sicker and see if we can actually spare them early death, or the need for a heart transplant, or a device,” Eduardo Marban said.

--Editors: Angela Zimm, Andrew Pollack

#<184845.409373.2.1.99.7.25># -0- Feb/14/2012 17:13 GMT

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Read the original here:
Scarred Hearts Can Be Mended With Stem Cell Therapy, Study Shows

VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates

Posted on by

SOUTH SAN FRANCISCO, CA--(Marketwire -02/14/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has identified its initial Top 10 drug rescue candidates and plans to launch two formal drug rescue programs by the end of next quarter.

VistaGen's goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development.

"We are now at an advanced stage in our business model," said Shawn Singh, VistaGen's Chief Executive Officer. "After more than a decade of focused investment in pluripotent stem cell research and development, we are now at the threshold where game-changing science becomes therapeutically relevant to patients and commercially relevant to our shareholders. We have positioned our company and our stem cell technology platform to pursue multiple large market opportunities. We plan to launch two drug rescue programs by the end of the next quarter."

Over the past year, VistaGen, working with its network of strategic partners, identified over 525 once-promising new drug candidates that meet the Company's preliminary screening criteria for heart toxicity-focused drug rescue using CardioSafe 3D™, its human heart cell-based bioassay system. After internally narrowing the field to 35 compounds, VistaGen, working together with its external drug rescue advisors, including former senior pharmaceutical industry executives with drug safety and medicinal chemistry expertise, analyzed and carefully narrowed the group of 35 to the current Top 10.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen's oral small molecule prodrug candidate, AV-101 (4-Cl-KYN), is in Phase 1b development for treatment of neuropathic pain. Unlike other NMDA receptor antagonists developed previously, AV-101 readily crosses the blood-brain barrier and is then efficiently converted into 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and specific glycineB site antagonists currently known, and has been shown to reduce seizures and excitotoxic neuronal death. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101. The Company anticipates pursuing Phase 2 development for neuropathic pain and other neurological indications, including depression, epilepsy, and/or Parkinson's disease in the event it receives additional non-dilutive development grant funding from the NIH or private foundations.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen's stem cell technology-based drug rescue activities, ongoing AV-101 clinical studies, its ability to enter into drug rescue collaborations and/or licensing arrangements with respect to one or more drug rescue variants, risks and uncertainties relating to the availability of substantial additional capital to support VistaGen's research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at http://www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

See original here:
VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates

Stem Cell Treatment Might Reverse Heart Attack Damage

Posted on by

MONDAY, Feb. 13 (HealthDay News) -- Stem cell therapy's promise for healing damaged tissues may have gotten a bit closer to reality. In a small, early study, heart damage was reversed in heart-attack patients treated with their own cardiac stem cells, researchers report.

The cells, called cardiosphere-derived stem cells, regrew damaged heart muscle and reversed scarring one year later, the authors say.

Up until now, heart specialists' best tool to help minimize damage following a heart attack has been to surgically clear blocked arteries.

"In our treatment, we dissolved scar and replaced it with living heart muscle. Such 'therapeutic regeneration' has long been the holy grail of cell therapy, but had never been accomplished before; we now seem to have done it," said study author Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles.

However, outside experts cautioned that the findings are preliminary and the treatment is far from ready for widespread use among heart-attack survivors.

The study, published online Feb. 14 in The Lancet, involved 25 middle-aged patients (average age 53) who had suffered a heart attack. Seventeen underwent stem cell infusions while eight received standard post-heart attack care, including medication and exercise therapy.

The stem cells were obtained using a minimally invasive procedure, according to the researchers from Cedars-Sinai and the Johns Hopkins Hospital in Baltimore.

Patients received a local anesthetic and then a catheter was threaded through a neck vein down to the heart, where a tiny portion of muscle was taken. The sample provided all the researchers needed to generate a supply of new stem cells -- 12 million to 25 million -- that were then transplanted back into the heart-attack patient during a second minimally invasive procedure.

One year after the procedure, the infusion patients' cardiac scar sizes had shrunk by about half. Scar size was reduced from 24 percent to 12 percent of the heart, the team said. In contrast, the patients receiving standard care experienced no scar shrinkage.

Initial muscle damage and healed tissue were measured using MRI scans.

After six months, four patients in the stem-cell group experienced serious adverse events compared with only one patient in the control group. At one year, two more stem-cell patients had a serious complication. However, only one such event -- a heart attack -- might have been related to the treatment, according to the study.

In a news release, Marban said that "the effects are substantial and surprisingly larger in humans than they were in animal tests."

Other experts were cautiously optimistic. Cardiac expert Dr. Bernard Gersh, a professor of medicine at Mayo Clinic, is not affiliated with the research but is familiar with the findings.

"This study demonstrates that it is safe and feasible to administer these cardiac-derived stem cells and the results are interesting and encouraging," he said.

Another specialist said that while provocative and promising, the findings remain early, phase-one research. "It's a proof-of-concept study," said interventional cardiologist Dr. Thomas Povsic, an assistant professor of medicine at the Duke Clinical Research Institute, in Durham, N.C.

And Dr. Chip Lavie, medical director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, in New Orleans, also discussed the results. He said that while the study showed that the cardiac stem cells reduced scar tissue and increased the area of live heart tissue in heart attack patients with moderately damaged overall heart tissue, it did not demonstrate a reduction in heart size or any improvement in the heart's pumping ability.

"It did not improve the ejection fraction, which is a very important measurement used to define the overall heart's pumping ability," Lavie noted. "Certainly, much larger studies of various types of heart attack patients will be needed before this even comes close to being a viable potential therapy for the large number of heart attack initial survivors."

Povsic concurred that much larger studies are needed. "The next step is showing it really helps patients in some kind of meaningful way, by either preventing death, healing them or making them feel better."

It's unclear what the cost will be, Povsic added. "What society is going to be willing to pay for this is going to be based on how much good it ends up doing. If they truly regenerate a heart and prevent a heart transplant, that would save a lot money."

Marban, who invented the stem cell treatment, said the while it would not replace bypass surgery or angioplasty, "it might be useful in treating 'irreversible' injury that may persist after those procedures."

As a rough estimate, he said that if larger, phase 2 trials were successful, the treatment might be available to the general public by about 2016.

More information

The U.S. National Heart, Lung, and Blood Institute describes current heart attack treatment.

Read the original post:
Stem Cell Treatment Might Reverse Heart Attack Damage

Stem Cells May Help Regenerate Heart Muscle

Posted on by

A promising stem cell therapy approach could soon provide a way to regenerate heart muscle damaged by heart attacks.

Researchers at Cedars-Sinai Heart Institute and The Johns Hopkins University harvested stem cells from the hearts of 17 heart attack patients and after prepping the cells, infused them back into the patients' hearts. Their study is published in the current issue of The Lancet.

The patients received the stem cell infusions about three months after their heart attacks.

Researchers found that six months after treatment, patients had significantly less scarring of the heart muscle and also showed a considerable increase the amount of healthy heart muscle, compared to eight post-heart attack patients studied who did not receive the stem cell infusions. One year after, scar size was reduced by about 50 percent.

"The damaged tissue of the heart was replaced by what looks like healthy myocardium," said Dr. Peter Johnston, a study co-author and an assistant professor of medicine at The Johns Hopkins University School of Medicine. "It's functioning better than the damaged myocardium in the control subjects, and there's evidence it's starting to contract and generate electrical signals the way healthy heart tissue does."

While this research is an early study designed to demonstrate that this stem cell therapy is safe, cardiologists say it's an approach that could potentially benefit millions of people who have suffered heart attacks. Damage to the heart muscle is permanent and irreparable, and little can be done to compensate for loss of heart function.

"In the U.S., six million patients have heart failure, and the vast majority have it because of a prior heart attack," said Johnston.

The damaged scar tissue that results from a heart attack diminishes heart function, which can ultimately lead to enlargement of the heart.

At best, Johnston said, there are measures doctors can try to reduce or compensate for the damage, but in many cases, heart failure ultimately sets in, often requiring mechanical support or a transplant.

"This type of therapy can save people's lives and reduce the chances of developing heart failure," he said.

Cardiac Regeneration A Promising Field

Other researchers have also had positive early results in experiments with stem cell therapy using different types of cells, including bone marrow cells and a combination of bone marrow and heart cells.

"It's exciting that studies using a number of different cell types are yielding similar results," said Dr. Joshua Hare, professor of cardiology and director of the University of Miami Interdisciplinary Stem Cell Institute.

The next steps, he said, include determining what the optimal cell types are and how much of the cells are needed to regenerate damaged tissue.

"We also need to move to larger clinical trials and measure whether patients are improving clinically and exhibiting a better quality of life after the therapy."

In an accompanying comment, Drs. Chung-Wah Siu amd Hung-Fat Tse of the University of Hong Kong wrote that given the promising results of these studies, health care providers will hopefully recognize the benefits that cardiac regeneration can offer.

And Hare added that someday, this type of regeneration can possibly offer hope to others who suffered other types of organ damage.

"This stategy might work in other organs," he said. "Maybe this can work in the brain, perhaps for people who had strokes."

Read the rest here:
Stem Cells May Help Regenerate Heart Muscle

Mitomics Announces U.S. Sales and Marketing Agreement with LabMD

Posted on by

THUNDER BAY, Ontario--(BUSINESS WIRE)--

Mitomics, a world leader in the research and development of mitochondrial genome-based products, today announced a non-exclusive agreement with LabMD, Inc., an Atlanta-based clinical pathology laboratory, to market Mitomics’ flagship product, the Prostate Core Mitomic Test™ (PCMT), in the United States.

“We are pleased to partner with LabMD to make PCMT available to their urology customers nationwide,” said Robert Poulter, president and chief executive officer of Mitomics. “LabMD has an outstanding reputation and strong track record of providing exceptional service to its customers. They continue to integrate cutting-edge technologies into their lab, and we have found great synergies between our two companies. This agreement supports our ongoing strategy to expand access to our prostate cancer testing technology through strategic collaborations as well as through direct sales by our field force.”

PCMT is a highly advanced test, based on the science of mitochondrial DNA (mtDNA), that accurately identifies a biomarker that can indicate the presence of cancerous cells using previously obtained prostate biopsy tissue. PCMT takes advantage of a tumor’s cancerization field effect to identify molecular changes and enable detection of missed tumors. The test’s sensitivity of 84 percent and ability to accurately rule out prostate cancer with a negative predictive value of 91 percent can provide reliable information to physicians and patients confronted with a possible prostate cancer diagnosis.

“Mitomics’ PCMT fits well within our current portfolio of clinical pathology tests, and we look forward to offering urologists this highly accurate test for patients with suspected prostate cancer who have a negative initial biopsy outcome,” said Michael Daugherty, founder, chief executive officer and president of LabMD. “We are committed to enhancing our service offerings and are excited to be working closely with Mitomics to increase the availability of PCMT.”

Prostate cancer is the most commonly diagnosed cancer in males and the second leading cause of cancer death in the U.S. Every year, more than 230,000 American men are diagnosed with prostate cancer, and more than 30,000 die from the disease. If detected early, prostate cancer is often treatable. It is estimated that well over 1 million prostate biopsies are performed annually in the U.S., and although approximately 70 percent of all initial prostate biopsies are negative, it has been found that anywhere from 25 to 60 percent of these are positive on second or subsequent biopsy.

About the Prostate Core Mitomic Test™ (PCMT)

A prostate cancer biopsy is neither an easy nor painless procedure and can result in multiple complications. It only samples a small fraction of the prostate gland, potentially missing the tumor and contributing to a high false negative rate – even in second biopsies. With the highly sensitive PCMT, you can know more by getting far more accurate and reliable results from biopsy tissue. PCMT is a highly advanced, proprietary test based on the science of mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy tissue, PCMT can determine the presence of malignant cells via a cancerization field effect by detecting underlying molecular alterations in normal-appearing tissue. This is all performed quickly and easily with a simple lab test. For more information or to order PCMT, please visit the PCMT web page.

About Mitomics

Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests that address significant unmet needs in oncology and gynecology, including those for the early detection of prostate and breast cancer, as well as a test for endometriosis. Mitomics currently markets the Prostate Core Mitomic Test™, a highly accurate laboratory developed test for detecting the absence or presence of cancerous cells using existing prostate biopsy tissue, and plans to launch several additional breakthrough molecular tests based on its Mitomic Technology™ in the coming years. The company is headquartered in Thunder Bay, Ontario, Canada. For more information, please visit http://www.mitomicsinc.com.

About LabMD, Inc.

LabMD is a privately held anatomic and clinical pathology laboratory that focuses on the Urology office based market. Through expert pathology practiced by our highly experienced uropathologists and LabMD's unique software solutions that streamline and bring efficiency to our clients, LabMD builds strong long-term client relationships. For more information, please contact LabMD at 678.443.2331.

Continue reading here:
Mitomics Announces U.S. Sales and Marketing Agreement with LabMD

Pronova BioPharma ASA: Expanding the Pharmaceutical Business into Clinical Nutrition

Posted on by

14 February 2012, Lysaker, Norway: Pronova BioPharma today announced results for the fourth quar­ter and full year 2011. Fourth quarter revenues were NOK 444.3 million, up 14 percent from a year before, and revenues for the year ended 31 December 2011 were NOK 1 668.9 million, up 2 percent from last year. EBITDA was NOK 197.1 million in the fourth quarter, up 53 percent year-on-year, and was NOK 705.3 million for the full year, up 13 percent from last year.

End-user demand in Pronova BioPharma`s current eight largest markets, as measured by IMS, grew by 5 percent in 2011, represent­ing total volumes of 1 273 tonnes. This represents USD 1.4 billion in drug sales, with Omacor®/Lovaza(TM) maintaining its status as a blockbuster product. During the year, GSK reached its expected inventory target for 2011. The reduction in demand was partially offset by higher off-take from other partners in Europe and Asia. Omacor®/Lovaza(TM) is currently sold in 57 markets, and the Group continues to expand its geographic reach.

The Board of Directors propose to adjust the existing dividend pol­icy to between 40 and 60 percent of net profit adjusted for pre-tax amortisation costs. The decision reflects the continued strong cash generation of Pronova BioPharma and the Company`s commitment to provide competitive returns to investors. The Company believes that adjusting for non cash amortisation costs better emphasises the strong cash conversion in the dividend policy. Furthermore, a more narrow range of 40 to 60 percent of adjusted net profit allows Pronova BioPharma to give a more targeted guidance to the financial community going forward. The Company will continue to evaluate annual dividends against the objectives of maintaining a solid financial position and investments to grow the business.

In line with the revised dividend policy, the Board of Directors pro­pose a first dividend of NOK 0.5 per share for 2011, corresponding to approximately 50 percent of net profit adjusted for pre-tax amortisation cost. This reflects the significant progress made towards the Company`s strategic objectives in 2011, which has strengthened the Company`s financial position and diversified its future cash generation capabilities.

Based on current market conditions, Pronova BioPharma main­tains its outlook for 2012, with shipments in line with underlying end-user demand and launches in new markets. Supply prices, as measured by the revenue-to-shipment ratio are expected to be in line with 2011 levels. The Company expects, all other things being equal, revenue and EBITDA growth in 2012.

However, as previously communicated, there is a risk of loss of exclusivity in Europe, where patents in most countries expired 30 months ago. There is also a risk of generic launch in the USA if the US District Court for the District of Delaware (District Court) rules against Pronova BioPharma in the litigation against Teva and Par, the US Food and Drug Administration (FDA) grants approval to the generic companies and API supply is available in sufficient volume. The Company expects a ruling within the next three months.

The Group today announced plans to expand its pharmaceuti­cal business into clinical nutrition. Clinical nutrition is nutrition taken under medical supervision and is provided in either enteral or parenteral form. The omega-3 market for clinical nutrition is estimated at 500 tonnes in 2011 and is expected to double in size within five years.

Pronova BioPharma plans to develop new clinical nutrition prod­ucts in collaboration with leading scientists and commercial partners. Products will be differentiated from existing offerings through such factors as concentration and purity levels, quality assurance, and health claims/scientific documentation.

Pronova BioPharma also continues to make progress in its research efforts to develop new drugs in the metabolic/cardiovascular/inflammatory treatment areas. The Group`s lead pipeline candidate PRC-4016, a new chemical entity for the treatment of combined dyslipidemia (abnormal blood lipid levels), is currently in Phase I trials. Dyslipidemia has been shown to play an important role in the development of cardiovascular risk. PRC-4016 is a structurally modified omega-3 fatty acid, which has shown in pre-clinical studies to have potent triglyceride and bad (non-HDL) cholesterol lowering effects while raising good (HDL) cholesterol. The trial is a double-blind, placebo-controlled, single and multiple oral dose study to investigate the safety, tolerability and pharmacokinetics of PRC-4016. The study, conducted in healthy volunteers, is being performed in the UK. The trial is progressing well and top line results are expected to be announced in Q2 2012.

In November 2011, Pronova BioPharma announced that it will develop a consumer healthcare business, entering the fast-growing Omega-3 consumer healthcare market. The business will initially target the high concentrate dietary supplement market, which is expected to double in size in the next five years. Since the announcement, Pronova BioPharma has made substantial pro­gress in developing this business. The manufacturing facility in Sandefjord, Norway has been selected to serve the consumer healthcare business and the necessary modifications are being implemented. The Company has also strengthened the manage­ment team with the appointment of Claus Kjærsgaard as VP of Consumer Healthcare and a number of experienced professionals are in the process of being hired for the new division. Claus brings 15 years of consumer healthcare experience across a diversity of categories, distribution channels and geographical environments.

Pronova BioPharma continues to extend its manufacturing advan­tages. In June 2011, the Group announced a target of increasing yield by 50 percent by the end of 2014 compared to 2009 levels. Pronova BioPharma is well on its way to achieving that target.

Pronova BioPharma`s Chief Executive Officer Morten Jurs com­mented, "In 2011, we continued to generate strong cash flow and made significant progress towards our strategic objectives. Our core pharmaceutical business continued to grow, and we launched our product in new markets. On the manufacturing side, we improved yield to further strengthen our competitive advantage in manufacturing versus potential market entrants. With our progress in R&D, expansion into clinical nutrition and our plans to launch a consumer healthcare business, we have made Pronova BioPharma a more diversified company and created new sources of growth. "

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)Report Q4 11
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Pronova BioPharma ASA via Thomson Reuters ONE
HUG#1585270

Read more:
Pronova BioPharma ASA: Expanding the Pharmaceutical Business into Clinical Nutrition

Research and Markets: South Africa In Vitro Diagnostics Market Outlook to 2017

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d22d0e/south_africa_in_vi) has announced the addition of GlobalData 's new report "South Africa In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" to their offering.

GlobalData's new report, South Africa In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture provides key market data on the South Africa In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope:

Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017. 2010 company shares and distribution shares data for each of the seven market categories. Global corporate-level profiles of key companies operating within the market.

Reasons to Buy:

Develop business strategies by identifying the key market categories and segments poised for strong growth. Develop market-entry and market expansion strategies. Design competition strategies by identifying who-stands-where in the South Africa In Vitro Diagnostics competitive landscape. Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what's the most preferred mode of product distribution? Identify, understand and capitalize.

Companies Mentioned:

Abbott Laboratories Alere Inc. Ani Labsystems Ltd Oy Beckman Coulter, Inc. Becton, Dickinson and Company bioMerieux S.A. Bio-Rad Laboratories, Inc. Chembio Diagnostic, Inc. DIAGNOSTICA STAGO, Inc. DiaSorin S.p.A F. Hoffmann-La Roche Ltd. Gen-Probe Incorporated Grifols, S.A. HORIBA, Ltd. Hologic, Inc. Immucor, Inc. Life Technologies Corporation Mindray Medical International Limited Ortho-Clinical Diagnostics Inc. PerkinElmer, Inc. Phadia AB Qiagen N.V. Siemens Healthcare Sysmex Corporation Thermo Fisher Scientific Inc.

For more information visit http://www.researchandmarkets.com/research/d22d0e/south_africa_in_vi

Original post:
Research and Markets: South Africa In Vitro Diagnostics Market Outlook to 2017

Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

Posted on by

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

http://www.reportlinker.com/p0771112/Leading-Microbiology-Market-Players-Insightful-Profiles-of-Major-Suppliers-and-Emerging-Market-Entrants.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This report presents strategic assessments of leading market players and emerging suppliers with innovative technologies and products in terms of their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Contains 90 pages

Table of Contents- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- Innogenetics/Solvay

- Ortho-Clinical Diagnostics

- Kreatech

- Life Technology

- Lonza

- Nanogen/Elitech

- Novartis Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

To order this report:In Vitro Diagnostic Industry: Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Visit link:
Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

Report seeks to integrate microbes into climate models

Posted on by

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

The models used to understand how Earth's climate works include thousands of different variables from many scientific including atmospherics, oceanography, seismology, geology, physics and chemistry, but few take into consideration the vast effect that microbes have on climate. Now, a new report from the American Academy of Microbiology, "Incorporating Microbial Processes into Climate Models", offers a plan for integrating the latest understanding of the science of microbiology into climate models.

"Climate scientists and microbiologists usually work in isolation from each other, and yet their work is intimately connected. Microbes are critical players in every geochemical cycle relevant to climate. The sum total of microbial activity is enormous, but the net effect of microbes on climate-relevant gases is currently not known," says Edward DeLong of the Massachusetts Institute of Technology, who co-chaired the report with Caroline Harwood of the University of Washington.

The past two decades have witnessed an explosion in scientific recognition of the diversity of the microbial world. New DNA-sequencing technologies spurred by the Human Genome Project have made it technically and economically possible to sequence the collective DNA from whole microbial communities. This approach, called metagenomics, has revealed a previously undreamed-of degree of diversity in the microbial world. These microbial community analyses many "'omics" approaches, such as proteomics and metabolomics, that together provide a detailed picture of community function, potential and change over time.

The report is based on a colloquium convened by the Academy in 2011. Experts in diverse disciplines in microbiology as well as computational and climate modeling participated in the meeting designed to identify specific efforts and activities that will lead to improved integration of microbial biology, biogeochemistry, and climate modeling.

"While the gap between these disciplines is daunting, the need to bridge it is urgent and the science and technology needed to begin to do so is within reach," says Harwood.

The report suggests a multipronged approach, breaking the challenge into manageable parts. The first recommendation is to choose a few specific biogeochemical cycles that are important, microbially driven and tractable to serve as demonstration projects. Specifically, the report identifies methane, carbon storage and nitrous oxide.

Other recommendations include:

Assess current data collection methodologies and develop a monitoring/data collection strategy Implement validation processes to integrate data collection, modeling and experimentation Facilitate and provide incentives for collaborations and interdisciplinary training Address technology needs

"There is clear evidence that microbes can have an enormous impact on climate.. In light of the increasingly urgent need to understand and find ways to mitigate climate change, the centrality of microbes in global biogeochemical cycles, can no longer be ignored," says DeLong.

###

A full copy of the report and more detailed recommendations can be found on the Academy website at http://bit.ly/aamclimate.

The American Academy of Microbiology is the honorific leadership group of the American Society for Microbiology. The mission of the Academy is to recognize scientific excellence, as well as foster knowledge and understanding in the microbiological sciences. A full list of Academy colloquia reports can be found at http://academy.asm.org/colloquia. For more information about the American Society for Microbiology, visit http://www.asm.org.

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

The rest is here:
Report seeks to integrate microbes into climate models

Emerging Microbiology Tests and Companies Developing New Technologies and Products

Posted on by

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Microbiology Tests and Companies Developing New Technologies and Products

http://www.reportlinker.com/p0771110/Emerging-Microbiology-Tests-and-Companies-Developing-New-Technologies-and-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This 650-page report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products.

Contains 650 pages and 47 tables

Table of Contents

1. AIDS

a. Background

0 Structure and Composition

0 Classification

0 Origin of AIDS

0 Animal Lentivirus Systems

0 Virus Receptos

0 HIV Infections in Humans

- Pathogenesis & Pathology: Overview of

HIV Infection Course

0 CD4T Lymphocytes and Memory Cells

0 Monocytes and Macrophages

0 Lymphoid Organs

0 Neural Cells

0 Viral Coinfections

- Clinical Findings

0 Plasma Viral Load

0 Pediatric AIDS

- Neurologic Disease

- Opportunistic Infections

- Cancer

0 Immunity

- Virus Isolation

- Serology

- Detection of Viral Nucleic

Acid and Antigens

0 Infectivity

0 Epidemiology

- Worldwide Spread of AIDS

- United States

- Routes of Transmission

b. Diagnostic Tests0 Laboratory Diagnosis- Enzyme Immunoassay Interpretation- Specific, Sensitivity, and PredictiveValue of Enzyme Immunoassays0 Competition Assays0 Western Blot Technique0 Immuno-Fluorescence Assay (IFA)0 Radioimmunoprecipitation0 HIV-1/HIV-2 Combination Testing0 Methods of HIV-Antigen Detection0 Antigen Assays and Blood Screening0 Urine Tests0 Immunopathogenic Mechanism of HIV Infection0 DNA Probes- Overview- Quantitative Polymerase Chain Reaction- In Situ PCR- Needed Improvements0 Viral Load/Drug Resistance Testing0 Genotype and Phenotype Testing0 Blood Banking Considerationc. Vaccines and Drugs- Antiviral Drugs- Vaccines Against HIV0 Transmission of HIV in Blood Products0 HIV Transmission in Transplant andArtificial Insemination Recipients2. Adenovirusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugsd. Adeno-Associated Viruses(AAV)3. Aeromonasa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs4. Anthrax/Bacillus Anthracisa. Background

b. Diagnostic Tests

c. Vaccines and Drugs

5. Arboviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

6. Babesiosis

a. Background

7. Bacillary Epithelioid Angiomatosis (BEA)

And Other Bartonella (Rochalimaea)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

8. Blastocystis Hominis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

9. Brucella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

10. Campylobacter

a. Background

b. Diagnostic Tests

0 Identification from Culture

c. Vaccines and Drugs

11. Candida

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

12. Chagas Disease

a. Background

13. Chancroid

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

14. Chlamydia

a. Background

0 Chlamydia Psittaci

0 Chlamydia Pneumoniae0 Chlamydia Trachomatisb. Diagnostic Testsc. Vaccines and Drugs15. Clostridium Difficilea. Background0 Pediatric Infections0 Epidemiologyb. Diagnostic Tests0 Counterimmunoelectrophoresis0 Fluorescent-Antibody Assays0 Poloymerase Chain Reactionsc. Drugs and Vaccines16. Coronavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs17. Coxsackievirusesa. Background0 Herpangina0 Hand-foot-and-mouth syndrome0 Hepidemic Conjuctivitis0 Pharingitis0 Epidemic Pleurodynia0 Myodarditis,Pericarditis0 Overwhelming Infection of the Newborn0 Acute Aseptic Meningitis0 Undifferentiated Febrile Illness0 Fever with upper respiratory infection0 Encephalitis0 Asymptomatic Infectionb. Diagnostic Testsc. Vaccines and Drugs18. Creutzfeldt-Jakob's Diseasea. Background0 Blood Transmissionb. Diagnostic Tests0 Major Commercial and Academic Players- Bayer

- Disease Sciences/Bio Tec Global

- Imperial College of Medicine

- Ortho-Clinical Diagnostics

- Pall

- ProMetic Life Sciences

- Proteome Sciences/Idexx

- Q-One Biotech

- Serono

- U.S. Agricultural Research Service

c. Vaccines

19. Cryptosporidium Parvum

a. Background

b. Diagnostic Tests

0 Histologic

0 Laboratory Parasitology

0 Serodiagnosis

c. Vaccines and Drugs

20. Cyclospora Cayetanensis

a. Background

0 Asymptomatic Infection

0 Diarrhea in Immunocompetent Persons

0 Diarrhea in Immunocompromisedersons

b. Diagnostic Tests

c. Vaccines and Drugs

21. Cytomegalovirus

a. Background

0 Chorioretinitis

0 Gastrointestinal

0 Central Nervous System Disease

b. Diagnostic Tests

c. Vaccines and Drugs

22. Ebola Virus

a. Background

0 Epidemiology

0 Hemorrhagic Fever

b. Diagnostic Tests

c. Vaccines and Drugs

23. E. Coli

a. Background

0 Role of Escherichia Coli inCausing Diarrhea0 EPEC0 ETEC0 EIEC0 EHECb. Diagnostic Testsc. Vaccines and Drugs24. EchoVirusa. Background0 Acute Aseptic Miningitisis0 Encephalitis0 Exanthems0 Respiratory Disease0 Myope;ricarditis0 Neonatal Infectionsb. Diagnostic Testsc. Vaccines and Drugs25. Encephalitisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs26. Enterovirusesa. Backgroundb. Diagnostic Tests0 Viral Isolation and Identification0 Antibody Testsc. Vaccines and Drugs27. Epstein-Barr Virusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs28. Giardia Lambliaa. Background0 Life Cycle and Morphology0 Morphology of Trophozoites0 Clinical Diseaseb. Diagnostic Testsc. Vaccines and Drugs

29. Gonorrhea

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

30. Granuloma Inguinale

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

31. Hantavirus

a. Background

0 Identification of the Agent

0 Transmission

0 Other Rodent Hantaviruses

0 Distribution

0 Hantavirus Diseases

0 Epidemiology

0 Addendum in Proof-Northeastern Connection

0 Previously Unknown Pathogens

0 Cases Nationwide

b. Diagnostic Tests

0 An Immunohistochemistry Approach

0 Hantavirus Rapid Diagnostic Test

0 ELISA Diagnosis of Hantavirus Pulmonary

Syndrome

0 IgG ELISA

0 IgM Capture ELISA

c. Vaccines and Drugs

32. Helicobacter Pylori

a. Background

0 Pathogenesis

0 Role in Peptic Ulcer Disease

0 Role in Gastric Cancer

0 Nonulcer Dyspepsia

b. Diagnostic Tests

c. Vaccines and Drugs

0 Specific Therapeutic Regimens

0 Who Should Be Treated?

0 Participants in Controlled Clinical Trials

0 Patients with Refractory Peptic Ulcer0 Patients with Refractory NUD0 Patients in High-Risk Groups for GastricCancer33. Hepatitisa. Backgroundb. Hepatitis Ac. Hepatitis Bd. Hepatitis C0 Classification0 Transmission of Infection0 Occupational Hazards0 Acute Hepatitis0 Diagnosis of Acute Infection0 Chronic Hepatitis0 HCV and Other Chronic Liver Diseases0 Alcoholic Liver Disease0 Hepatitis B Coinfection0 Cirrhosis and Hepatocellular Carcinoma0 Diagnostic Tests0 Possible Indications for HCV RNA Testing0 Conclusions and Future Directione. Hepatitis D0 Historical Perspective0 Epidemiology0 HBV-HDV "Coinfection" vs. "Superinfection"0 Methods of Detecting HDV0 Preventionf. Hepatitis E0 Background0 Prevalence of the Disease0 Diagnostic Tests0 Epidemiologic Serosurveys0 Serologic Cross-Reactivityg. Hepatitis G0 Vaccines and Drugs34. Herpes Simplex Virusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)

a. Background

0 HIV-6 Infections

b. Diagnostic Tests

c. Vaccines and Drugs

36. Influenza Viruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

37. Legionella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

38. Lyme Disease

a. Background

0 Clinical Description

0 Clinical Case Definition

0 Laboratory Criteria for Diagnosis

0 Case Classification

b. Diagnostic Tests

c. Vaccines and Drugs

39. Lymphogranuloma Venereum (LGV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

40. Malaria

a. Background

b. Diagnostic Tests

0 Potential Diagnositic Problems with Positive

Patients from Non-endemic Areas

- Patient

- Laboratory

- Physician

c. Vaccines and Drugs

41. Measles (Rubeola)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

42. Meningitisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Development of Polysaccharide Vaccines0 Quadrivalent Vaccine Development0 Meningococcal A.C.Y. & W-135 Vaccines0 Efficacy of Group C Vaccine0 Efficacy of Group A Vaccine0 Combinations of Group A and C Vaccines0 Group B Efficacy Trials0 Future Direction43. Microsporidiuma. Background0 Prevalence and Geographic Distribution0 Sources of Human Infection and Transmissionb. Diagnostic Tests0 Light Microscopic Examination of StoolSpecimens By Chromotrope Staining0 Stool Concentration Methods0 Chemofluorescent Agents0 Giemsa Staining of Stool Specimens0 Cytologic Diagnosis0 Histologic Examination0 Electron Microscopy0 Examination of Bodily Fluids0 Examination of Tissue Sections0 Immunofluorescence Detection Procedures0 Serology0 Cell Culture0 Approach to Diagnosis0 Evaluation of Patients with PresumptiveIntestinal Microsporidiosis0 Evaluation of Patients with PresumptiveOcular Microsporidiosisc. Vaccines and Drugs44. Mononucleosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

45. Mumps

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Efficacy of Vaccination

0 Future Issues

46. Mycoplasma

a. Background

0 Ureaplasma Urealyticum & Mycoplasma Hominis

b. Diagnostic Tests

c. Vaccines and Drugs

47. Papillomaviruses

a. Background

0 HPV in Cancer

0 Cervical Neoplasm

b. Diagnostic Tests

c. Vaccines and Drugs

0 Prevention

48. Parvovirus B19

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

49. Pneumonia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

50. Polyomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

51. Pseudomonas Aeruginosa

a. Background

0 Virulence Factors

b. Diagnostic Tests

c. Vaccines and Drugs

52. Rabies

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs54. RhinoVirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs55. RotaVirus (REOVIRUS)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs56. Rubella(MEASLES)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Developing Countries0 Elimination and Eradication of Measles0 New Developments57. Salmonellosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs58. Septicemiaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs59. Shigellosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs60. Staphylococcus Aureusa. Background0 The Genus Taphylococcusb. Diagnostic Testsc. Vaccines and Drugs0 Prevention61. Streptococcia. Backgroundb. Diagnostic Tests

c. Vaccines and Drugs

0 Group A Streptococci

0 Group B Streptococci

62. Syphilis

a. Background

b. Diagnostic Tests

0 Biopsy

0 Rabbit Infectivity Testing

0 Other Diagnostic Modalities

c. Vaccines and Drugs

0 Syphilis and HIV Infection

0 Syphilis As a Cofactor for HIV Transmission

0 Basic Science Issues

63. Toxoplasmosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

64. Trichomonas Vaginalis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

65. Tuberculosis

a. Background

b. Diagnostic Tests

0 Microscopic Characteristics

0 Cultural Characteristics

0 Detection of Antibodies

0 Skin Tests

0 MDRTB

c. Vaccines and Drugs

66. Vibrio

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

67. West Nile Virus

a. Background

- Clinical Syndromes

b. Diagnostic Tests

c. Vaccines and Drugs

68. Yersinaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

List of Tables

Major Companies Developing or Marketing AIDS TestsMajor Companies Developing or Marketing AdenovirusTestsMajor Companies Developing or Marketing BartonellaTestsMajor Companies Developing or MarketingCampylobacter TestsMajor Companies Developing or Marketing CandidaTestsMajor Companies Developing or Marketing ChlamydiaTestsMajor Companies Developing or Marketing ClostridiumTestsMajor Companies Developing or Marketing CoronavirusTestsMajor Companies Developing or Marketing CryptosporidiumTestsMajor Companies Developing or Marketing CMV TestsMajor Companies Developing or Marketing EchovirusTestsMajor Companies Developing or Marketing EnterovirusTestsMajor Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing MicrosporidiumTestsMajor Companies Developing or MarketingMononucleosis TestsMajor Companies Developing or Marketing Mumps TestsMajor Companies Developing or Marketing MycoplasmaTestsMajor Companies Developing or Marketing PapillomaVirus TestsMajor Companies Developing or Marketing ParvovirusTestsMajor Companies Developing or Marketing PneumoniaTestsMajor Companies Developing or Marketing RSV TestsMajor Companies Developing or Marketing RotavirusTestsMajor Companies Developing or Marketing RubellaTestsMajor Companies Developing or Marketing SalmonellaTestsMajor Companies Developing or Marketing SepticemiaTestsMajor Companies Developing or Marketing ShigellaTestsMajor Companies Developing or Marketing StaphylococciTests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

To order this report:In Vitro Diagnostic Industry: Emerging Microbiology Tests and Companies Developing New Technologies and Products

More  

Market Research Report

Check our  

Industry Analysis and Insights

 

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Read this article:
Emerging Microbiology Tests and Companies Developing New Technologies and Products

Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

Posted on by

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

http://www.reportlinker.com/p0771111/Future-Microbiology-Testing-Market-Facilities-Test-Volumes-and-Sales-Forecasts-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This report provides a worldwide overview of the microbiology testing market environment, structure, size and growth. Includes estimates of the number of laboratories performing microbiology tests, as well as ten-year test volume and sales forecasts by country.

Contains 15 pages and 3 tables

Table of Contents1. Worldwide Business Environment

2. Worldwide Market Structure

3. Worldwide Market Size and Growth

List of TablesTable 1: Laboratories Performing Microbiology Tests by Country

Table 2: Total Microbiology Test Volume Forecast by Country

Table 3: Total Microbiology Diagnostics Market Forecast by Country

To order this report:In Vitro Diagnostic Industry: Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

See the article here:
Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

Future US Microbiology Testing Market Outlook

Posted on by

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future US Microbiology Testing Market Outlook

http://www.reportlinker.com/p0771120/Future-US-Microbiology-Testing-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Complete report $9,400.  DataPack (test volumes, sales forecasts, supplier shares) $3,450.

Highlights

Comprehensive 1,037-page analysis of the US microbiology testing market. Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in US hospitals, blood banks, physician offices, public health and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of leading suppliers. Emerging diagnostic technologies and their potential market applications. Product development opportunities. Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers.

Contains 1,037 pages and 177 tables

US MICROBIOLOGY TESTING MARKETTable of ContentsIntroductionWorldwide Market and Technology OverviewA. Major Infectious Disease Tests1. AIDSa. Background0 Structure and Composition0 Classification0 Origin of AIDS0 Animal Lentivirus Systems0 Virus Receptos0 HIV Infections in Humans- Pathogenesis & Pathology: Overview ofHIV Infection Course0 CD4T Lymphocytes and Memory Cells0 Monocytes and Macrophages0 Lymphoid Organs0 Neural Cells0 Viral Coinfections- Clinical Findings0 Plasma Viral Load0 Pediatric AIDS- Neurologic Disease- Opportunistic Infections- Cancer0 Immunity- Virus Isolation- Serology- Detection of Viral NucleicAcid and Antigens0 Infectivity0 Epidemiology- Worldwide Spread of AIDS- United States- Routes of Transmission

b. Diagnostic Tests

0 Laboratory Diagnosis

- Enzyme Immunoassay Interpretation

- Specific, Sensitivity, and Predictive

Value of Enzyme Immunoassays

0 Competition Assays

0 Western Blot Technique

0 Immuno-Fluorescence Assay (IFA)

0 Radioimmunoprecipitation

0 HIV-1/HIV-2 Combination Testing

0 Methods of HIV-Antigen Detection

0 Antigen Assays and Blood Screening

0 Urine Tests

0 Immunopathogenic Mechanism of HIV Infection

0 DNA Probes

- Overview

- Quantitative Polymerase Chain Reaction

- In Situ PCR

- Needed Improvements

0 Viral Load/Drug Resistance Testing

0 Genotype and Phenotype Testing

0 Blood Banking Consideration

c. Vaccines and Drugs

- Antiviral Drugs

- Vaccines Against HIV

0 Transmission of HIV in Blood Products

0 HIV Transmission in Transplant and

Artificial Insemination Recipients

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Testsc. Vaccines and Drugs5. Arbovirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs6. Babesiosisa. Background7. Bacillary Epithelioid Angiomatosis (BEA)And Other Bartonella (Rochalimaea)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs8. Blastocystis Hominisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs9. Brucellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs10. Campylobactera. Backgroundb. Diagnostic Tests0 Identification from Culturec. Vaccines and Drugs11. Candidaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs12. Chagas Diseasea. Background13. Chancroida. Backgroundb. Diagnostic Testsc. Vaccines and Drugs14. Chlamydiaa. Background0 Chlamydia Psittaci

0 Chlamydia Pneumoniae

0 Chlamydia Trachomatis

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

0 Pediatric Infections

0 Epidemiology

b. Diagnostic Tests

0 Counterimmunoelectrophoresis

0 Fluorescent-Antibody Assays

0 Poloymerase Chain Reactions

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

0 Herpangina

0 Hand-foot-and-mouth syndrome

0 Hepidemic Conjuctivitis

0 Pharingitis

0 Epidemic Pleurodynia

0 Myodarditis,Pericarditis

0 Overwhelming Infection of the Newborn

0 Acute Aseptic Meningitis

0 Undifferentiated Febrile Illness

0 Fever with upper respiratory infection

0 Encephalitis

0 Asymptomatic Infection

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

0 Blood Transmission

b. Diagnostic Tests

0 Major Commercial and Academic Players

- Bayer

- Disease Sciences/Bio Tec Global- Imperial College of Medicine- Ortho-Clinical Diagnostics- Pall- ProMetic Life Sciences- Proteome Sciences/Idexx- Q-One Biotech- Serono- U.S. Agricultural Research Servicec. Vaccines19. Cryptosporidium Parvuma. Backgroundb. Diagnostic Tests0 Histologic0 Laboratory Parasitology0 Serodiagnosisc. Vaccines and Drugs20. Cyclospora Cayetanensisa. Background0 Asymptomatic Infection0 Diarrhea in Immunocompetent Persons0 Diarrhea in Immunocompromisedersonsb. Diagnostic Testsc. Vaccines and Drugs21. Cytomegalovirusa. Background0 Chorioretinitis0 Gastrointestinal0 Central Nervous System Diseaseb. Diagnostic Testsc. Vaccines and Drugs22. Ebola Virusa. Background0 Epidemiology0 Hemorrhagic Feverb. Diagnostic Testsc. Vaccines and Drugs23. E. Colia. Background

0 Role of Escherichia Coli in

Causing Diarrhea

0 EPEC

0 ETEC

0 EIEC

0 EHEC

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

0 Acute Aseptic Miningitisis

0 Encephalitis

0 Exanthems

0 Respiratory Disease

0 Myope;ricarditis

0 Neonatal Infections

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

0 Viral Isolation and Identification

0 Antibody Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

0 Life Cycle and Morphology

0 Morphology of Trophozoites

0 Clinical Disease

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrheaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs30. Granuloma Inguinalea. Backgroundb. Diagnostic Testsc. Vaccines and Drugs31. Hantavirusa. Background0 Identification of the Agent0 Transmission0 Other Rodent Hantaviruses0 Distribution0 Hantavirus Diseases0 Epidemiology0 Addendum in Proof-Northeastern Connection0 Previously Unknown Pathogens0 Cases Nationwideb. Diagnostic Tests0 An Immunohistochemistry Approach0 Hantavirus Rapid Diagnostic Test0 ELISA Diagnosis of Hantavirus PulmonarySyndrome0 IgG ELISA0 IgM Capture ELISAc. Vaccines and Drugs32. Helicobacter Pyloria. Background0 Pathogenesis0 Role in Peptic Ulcer Disease0 Role in Gastric Cancer0 Nonulcer Dyspepsiab. Diagnostic Testsc. Vaccines and Drugs0 Specific Therapeutic Regimens0 Who Should Be Treated?0 Participants in Controlled Clinical Trials

0 Patients with Refractory Peptic Ulcer

0 Patients with Refractory NUD

0 Patients in High-Risk Groups for Gastric

Cancer

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

0 Classification

0 Transmission of Infection

0 Occupational Hazards

0 Acute Hepatitis

0 Diagnosis of Acute Infection

0 Chronic Hepatitis

0 HCV and Other Chronic Liver Diseases

0 Alcoholic Liver Disease

0 Hepatitis B Coinfection

0 Cirrhosis and Hepatocellular Carcinoma

0 Diagnostic Tests

0 Possible Indications for HCV RNA Testing

0 Conclusions and Future Direction

e. Hepatitis D

0 Historical Perspective

0 Epidemiology

0 HBV-HDV "Coinfection" vs. "Superinfection"

0 Methods of Detecting HDV

0 Prevention

f. Hepatitis E

0 Background

0 Prevalence of the Disease

0 Diagnostic Tests

0 Epidemiologic Serosurveys

0 Serologic Cross-Reactivity

g. Hepatitis G

0 Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)a. Background0 HIV-6 Infectionsb. Diagnostic Testsc. Vaccines and Drugs36. Influenza Virusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs37. Legionellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs38. Lyme Diseasea. Background0 Clinical Description0 Clinical Case Definition0 Laboratory Criteria for Diagnosis0 Case Classificationb. Diagnostic Testsc. Vaccines and Drugs39. Lymphogranuloma Venereum (LGV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs40. Malariaa. Backgroundb. Diagnostic Tests0 Potential Diagnositic Problems with PositivePatients from Non-endemic Areas- Patient- Laboratory- Physicianc. Vaccines and Drugs41. Measles (Rubeola)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Development of Polysaccharide Vaccines

0 Quadrivalent Vaccine Development

0 Meningococcal A.C.Y. & W-135 Vaccines

0 Efficacy of Group C Vaccine

0 Efficacy of Group A Vaccine

0 Combinations of Group A and C Vaccines

0 Group B Efficacy Trials

0 Future Direction

43. Microsporidium

a. Background

0 Prevalence and Geographic Distribution

0 Sources of Human Infection and Transmission

b. Diagnostic Tests

0 Light Microscopic Examination of Stool

Specimens By Chromotrope Staining

0 Stool Concentration Methods

0 Chemofluorescent Agents

0 Giemsa Staining of Stool Specimens

0 Cytologic Diagnosis

0 Histologic Examination

0 Electron Microscopy

0 Examination of Bodily Fluids

0 Examination of Tissue Sections

0 Immunofluorescence Detection Procedures

0 Serology

0 Cell Culture

0 Approach to Diagnosis

0 Evaluation of Patients with Presumptive

Intestinal Microsporidiosis

0 Evaluation of Patients with Presumptive

Ocular Microsporidiosis

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumpsa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Efficacy of Vaccination0 Future Issues46. Mycoplasmaa. Background0 Ureaplasma Urealyticum & Mycoplasma Hominisb. Diagnostic Testsc. Vaccines and Drugs47. Papillomavirusesa. Background0 HPV in Cancer0 Cervical Neoplasmb. Diagnostic Testsc. Vaccines and Drugs0 Prevention48. Parvovirus B19a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs49. Pneumoniaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs50. Polyomavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs51. Pseudomonas Aeruginosaa. Background0 Virulence Factorsb. Diagnostic Testsc. Vaccines and Drugs52. Rabiesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Developing Countries

0 Elimination and Eradication of Measles

0 New Developments

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

0 The Genus Taphylococcus

b. Diagnostic Tests

c. Vaccines and Drugs

0 Prevention

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs0 Group A Streptococci0 Group B Streptococci62. Syphilisa. Backgroundb. Diagnostic Tests0 Biopsy0 Rabbit Infectivity Testing0 Other Diagnostic Modalitiesc. Vaccines and Drugs0 Syphilis and HIV Infection0 Syphilis As a Cofactor for HIV Transmission0 Basic Science Issues63. Toxoplasmosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs64. Trichomonas Vaginalisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs65. Tuberculosisa. Backgroundb. Diagnostic Tests0 Microscopic Characteristics0 Cultural Characteristics0 Detection of Antibodies0 Skin Tests0 MDRTBc. Vaccines and Drugs66. Vibrioa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs67. West Nile Virusa. Background- Clinical Syndromesb. Diagnostic Testsc. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review and Market Needs

0 Abbott AxSYM

0 Abbott IMx/IMx Select

0 Anagen AN2000/AuraFlex

0 Beckman Coulter Access

0 BioChem Pharma/SR1

0 BioMerieux/Vitek Vidas

0 Biotrol System 7000

0 Chiron ACS: Centaur

0 Chiron ACS: 180

0 J&J Diagnostics/Amersham Amerlite

0 J&J Diagnostics Vitros ECi

0 Olympus PK310

0 Roche Cobas Core

0 Roche Elecsys 1010/2010

0 Roche ES 22

0 Roche ES 33

0 Roche ES 300/300AL

0 Siemens ELISA Processor II/III

0 Siemens Immuno 1

0 Siemens/Opus/Plus/Magnum

0 Siemens Stratus

0 Tosoh AIA-1200/1200DX/NexIA/600

0 Wallac/Pharmacia Delfia

C. Emerging Diagnostic Technologies

1. DNA Probes

a. Technology Overview

b. Amplification Methods

0 Polymerase Chain Reaction

- Robotics

- Temperature Cyclers

- PCR Variations

0 Immuno-PCR

0 QC-PCR

0 DAP-PCR

0 Ligase Chain Reaction0 Branched DNA0 Q-Beta Replicase0 Nucleic-Acid Sequence-Based0 Strand Displacement Activation0 Self-Sustained Sequence Replicase2. Monoclonal Antibodies3. Immunoassaysa. Technological Principleb. Enzyme Immunoassays (EIA)0 Overview0 ELISA0 Dot Immunobinding Assays0 Capillary Immunoassays0 Particle-Membrane CaptureImmunoassays0 Enzyme Amplificationc. Fluorescent Immunoassays0 Fluorescence Polarization0 Time-Resolved Pulse Fluorescenced. Luminescence0 Chemiluminescence0 Bioluminescencee. Latex Agglutinationf. Immunoprecipitation4. Differential Light Scattering5. Microcomputers and Automation6. Artificial Intelligence7. Liposomes8. Flow Cytometry9. Chromatography10. MRI11. Gel Microdroplets12. OtherD. Personal TestingE. Worldwide Business EnvironmentF. Worldwide Market StructureG. Worldwide Market Size and Growth

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Reimbursement

4. Industry Consolidation

5. Managed Care

a. HMO

b. PPO

6. Hospitals

7. Admissions

8. Length of Stay

9. Industry Diversification

10. Physician Demographics

11. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

12. Laboratory Regulations

13. FDA Reform

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

c. Blood Banks

1) Community and Regional Centers

2) Plasma Fractionation Centers

2. Decentralized Testing

a. Physician Offices/Group Practices

b. Point of Care Testing

c. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers

Major Product Development OpportunitiesA. InstrumentationB. Reagent Kits and Test Systems/PanelsC. Computers, Software and AutomationD. Auxiliary ProductsDesign Criteria for Decentralized Testing ProductsAlternative Market Penetration StrategiesA. Internal DevelopmentB. Collaborative ArrangementsC. University ContractsD. Distribution Strategies for DecentralizedTesting Markets1. Marketing Approaches2. Product Complexity3. Customer Preference4. Established Suppliers5. Emerging Suppliers6. Major Types of Distributors7. Market SegmentationPotential Market Entry Barriers and RisksA. Market MaturityB. Cost ContainmentC. CompetitionD. Technological Edge and LimitationsE. Patent ProtectionF. Regulatory ConstraintsG. Decentralized Testing Market ChallengesCompetitive Assessments- Abbott- Affymetrix- Beckman Coulter- Becton Dickinson- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- J&J Diagnostics

- Kreatech

- Life Technology

- Lonza

- Nanogen

- Novartis Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

List of Tables

Major Companies Developing or Marketing AIDS TestsMajor Companies Developing or Marketing AdenovirusTestsMajor Companies Developing or Marketing BartonellaTestsMajor Companies Developing or MarketingCampylobacter TestsMajor Companies Developing or Marketing CandidaTestsMajor Companies Developing or Marketing ChlamydiaTestsMajor Companies Developing or Marketing ClostridiumTestsMajor Companies Developing or Marketing CoronavirusTestsMajor Companies Developing or Marketing CryptosporidiumTestsMajor Companies Developing or Marketing CMV TestsMajor Companies Developing or Marketing EchovirusTestsMajor Companies Developing or Marketing EnterovirusTestsMajor Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing MicrosporidiumTestsMajor Companies Developing or MarketingMononucleosis TestsMajor Companies Developing or Marketing Mumps TestsMajor Companies Developing or Marketing MycoplasmaTestsMajor Companies Developing or Marketing PapillomaVirus TestsMajor Companies Developing or Marketing ParvovirusTestsMajor Companies Developing or Marketing PneumoniaTestsMajor Companies Developing or Marketing RSV TestsMajor Companies Developing or Marketing RotavirusTestsMajor Companies Developing or Marketing RubellaTestsMajor Companies Developing or Marketing SalmonellaTestsMajor Companies Developing or Marketing SepticemiaTestsMajor Companies Developing or Marketing ShigellaTestsMajor Companies Developing or Marketing StaphylococciTests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

Worldwide All Market Segments Laboratories

Performing Microbiology Tests by Country

Worldwide All Market Segments Total Microbiology Test

Volume Forecast by Country

Worldwide All Market Segments Total Microbiology

Diagnostics Market Forecast by Country

Infectious Disease Tests Major Issues and Market

Potential For Personal Testing

U.S.A. Summary Table

All Infectious Diseases Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.

Laboratories Performing Infectious Disease Tests

by Market Segment

U.S.A.Hospital Laboratories Performing Infectious DiseaseTests by Bed SizeU.S.A.Commercial/Private Laboratories Performing InfectiousDisease Tests by Annual Test VolumeU.S.A.Physician Office Laboratories Performing InfectiousDisease Tests by Practice SizeU.S.A.All Market Segments Infectious Disease Test Volume ForecastU.S.A.Hospital Laboratories Infectious Disease Test Volume ForecastU.S.A.Blood Banks Infectious Disease Test Volume ForecastU.S.A.Physician Office Laboratories Infectious DiseaseTest Volume ForecastU.S.A.Commercial/Private Laboratories Infectious DiseaseTest Volume ForecastU.S.A.Public Health Laboratories Infectious Disease TestVolume ForecastU.S.A.All Market Segments Infectious Disease DiagnosticsMarket ForecastU.S.A.Hospital Laboratories Infectious Disease DiagnosticsMarket Forecast

U.S.A.

Blood Banks Infectious Disease Diagnostics Market Forecast

U.S.A.

Physician Office Laboratories Infectious Disease

Diagnostics Market Forecast

U.S.A.

Commercial/Private Laboratories Infectious Disease

Diagnostics Market Forecast

U.S.A.

Public Health Laboratories Infectious Disease

Diagnostics Market Forecast

U.S.A.

HIV or HIVI/HIVII Test Volume and Diagnostics Sales

Forecast by Market Segment

U.S.A.

HTLV I or HTLV I/HTLV II Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.

HIVAg Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Western Blot/Other Confirmatory Test Volume and

Diagnostics Sales Forecast by Market Segment

U.S.A.

Adenovirus Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Aeromonads Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.BEA Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Blastocystis Hominis Test Volume and Diagnostics SalesForecast by Market SegmentU.S.A.Campylobacter Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Candida Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Chancroid Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Chlamydia Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Clostridium Test Volume and Diagnostics Sales Forecast byMarketSegmentU.S.A.Coronavirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.CoxsackieVirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Cryptosporidium Test Volume and Diagnostics SalesForecast by Market Segment

U.S.A.

Cyclospora Test Volume and Diagnostics Sales

Forecast by Market Segment

U.S.A.

CMV Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

E. Coli Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Echovirus Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Encephalitis Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Enterovirus Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

EBV Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Giardia Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Gonorrhea Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Granuloma Inguinale Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.Hantavirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Helicobacter Pylori Test Volume and DiagnosticsSales Forecast by Market SegmentU.S.A.HAV NAT Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.HBV NAT Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.HbsAg Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Hepatitis C Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Anti-HBC Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Anti-HBS Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Anti-HAV Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Hepatitis Delta Test Volume and Diagnostics SalesForecast by Market Segment

U.S.A.

HBcAg Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

HBeAg Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

ALT/SGPT Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Herpes Simplex I and II Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.

Herpes Type VI Test Volume and Diagnostics Sales

Forecast by Market Segment

U.S.A.

Influenza Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Legionella Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Lyme Disease Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Lymphogranuloma Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Malaria Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.Measles Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Meningitis Test Volume and Diagnostics Sales Forecast byMarketSegmentU.S.A.Microsporidium Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Mononucleosis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Mumps Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Mycoplasma Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Papilloma Virus Test Volume and Diagnostics SalesForecast by Market SegmentU.s.a.Parvovirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Pneumonia Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Polyomaviruses Test Volume and Diagnostics Sales Forecast byMarket Segment

U.S.A.

Pseudomonas Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Rabies

Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

RSV

Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

Rhinovirus Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Rotavirus Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Rubella Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Salmonella Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Septicemia Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Shigella Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.Staphylococci Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Streptococci Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Syphilis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Toxoplasmosis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Trichomonas Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Tuberculosis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Vibrio Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.West Nile Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Yersinia Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.AIDS Testing Market Diagnostics Sales by MajorSupplier

U.S.A.

Adenovirus Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Campylobacter Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Candida Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Chancroid Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Chlamydia Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

CMV Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Cryptosporidium Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Echovirus Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Enterovirus Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

EBV Testing Market Diagnostics Sales by Major

Supplier

U.S.A.Giardia Testing Market Diagnostics Sales by MajorSupplierU.S.A.Gonorrhea Testing Market Diagnostics Sales by MajorSupplierU.S.A.Helicobacter Pylori Testing Market Diagnostics Sales by MajorSupplierU.S.A.Hepatitis Testing Market Diagnostics Sales by MajorSupplierU.S.A.Hepatitis C Testing Market Diagnostics Sales byMajor SupplierU.S.A.Herpes Testing Market Diagnostics Sales by MajorSupplierU.S.A.Influenza Testing Market Diagnostics Sales by MajorSupplierU.S.A.Legionella Testing Market Diagnostics Sales byMajor SupplierU.S.A.Lyme Disease Testing Market Diagnostics Sales byMajor SupplierU.S.A.Measles Testing Market Diagnostics Sales byMajor Supplier

U.S.A.

Meningitis Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Mononucleosis Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Mumps Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Mycoplasma Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Pneumonia Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Rabies Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

RSV Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Rotavirus Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Rubella Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Salmonella Testing Market Diagnostics Sales by

Major Supplier

U.S.A.Septicemia Testing Market Diagnostics Sales byMajor SupplierU.S.A.Shigella Testing Market Diagnostics Sales by MajorSupplierU.S.A.Streptococci Testing Market Diagnostics Sales byMajor SupplierU.S.A.Syphilis Testing Market Diagnostics Sales by MajorSupplierU.S.A.Toxoplasmosis Testing Market Diagnostics Sales byMajor Supplier

To order this report:In Vitro Diagnostic Industry: Future US Microbiology Testing Market Outlook

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Read more:
Future US Microbiology Testing Market Outlook

Home Care Assistance Launches AgingAdult.org

Posted on by

AgingAdult.org provides people curious to learn more about healthy longevity with scientifically based lifestyle tips and advice to help inspire them to live healthier and happier lives at any age

Palo Alto, CA (PRWEB) February 13, 2012

Home Care Assistance, the leading provider of in-home care for seniors, is proud to announce the launch of AgingAdult.org. Initially conceptualized as a resource for aging adults looking to learn more about healthy longevity, initial response to the website has come from a wide spectrum of age groups. By filling out the form on the website, individuals will automatically receive the downloadable version of the renowned aging book Happy to 102, a popular book that provides practical lifestyle tips and advice for not only living longer, but living well longer. This is a valuable resource for anyone interesting in healthy aging. The book is based on years of research following the inhabitants of the island of Okinawa in Japan, referred to as the best place for aging given that it has the highest life expectancy for men and women over the age of 65, and distills it into accessible lifestyle advice. In addition to being a highly engaging and enjoyable read, Happy to 102 provides guidance on the lifestyle behaviors and psychology that promote quality of life and aging well.

“AgingAdult.org is one of many consumer educational initiatives we are developing to provide education around the types of topics that our clients and the community have voiced an interest in learning more about,” said Kathryn Zakskorn, Public Relations and Marketing Manager of Home Care Assistance. “With an aging population comes an increased desire to learn about healthy longevity and we are excited to be able to provide this information in an accessible way.”

Whether you are a young adult looking to expand your knowledge of healthy longevity, a family caregiver wanting to learn more about aging well so that you can share that information with your loved one or an aging adult hoping to find practical advice to help you make the optimal lifestyle choices to ensure healthy nutrition and exercise, an active mind and a sense of calmness and purpose, AgingAdult.org will be an extremely valuable resource.

“It is profoundly liberating to let go of the belief that your life expectancy is predetermined solely based on genetic factors and instead embrace the view that you are in charge of your own longevity journey through the healthy lifestyle choices you make,” said Shadi Gholizadeh, Business Operations Manager of Home Care Assistance. “Our mission at Home Care Assistance is to change the way the world ages; we believe in empowering people to be proactive and informed when it comes to their health.”

For more information about Home Care Assistance please visit http://www.HomeCareAssistance.com or call 1-866-454-8346.

ABOUT HOME CARE ASSISTANCE

Home Care Assistance is the leading provider of home care for seniors across the United States and Canada. Our mission is to change the way the world ages. We provide older adults with quality care that enables them to live happier, healthier lives at home. Our services are distinguished by the caliber of our caregivers, the responsiveness of our staff and our expertise in Live-In care. We embrace a positive, balanced approach to aging centered on the evolving needs of older adults. A 2012 Franchise500® Company, Home Care Assistance has received numerous industry awards including Entrepreneur’s Fastest-Growing Franchises and Franchise Business Review’s Top 50. For more information about Home Care Assistance, our services and franchise opportunities, visit homecareassistance.com or franchise.homecareassistance.com.

###

Kathryn Zakskorn
Home Care Assistance
650-462-9501
Email Information

View post:
Home Care Assistance Launches AgingAdult.org

Prudential Retirement reinsures retirement benefits through transaction with Rothesay Life

Posted on by

NEWARK, N.J.--(BUSINESS WIRE)--

Prudential Retirement, a business unit of Prudential Financial, Inc. (NYSE: PRU - News), today announced its first longevity reinsurance transaction of 2012.

Under the terms of the transaction, Prudential Retirement will provide reinsurance of longevity risk to Rothesay Life, a wholly-owned subsidiary of The Goldman Sachs Group, Inc. The transaction initially covers pension liability values of GBP 423 million, approximately equal to $665 million U.S. dollars.

The reinsurance secures the retirement benefits of almost 20,000 members of the Uniq Plc Pension Scheme, who are insured by Rothesay Life. The reinsurance transaction is particularly significant as it covers the risks of all life annuities held by plan participants, regardless of age or retirement status, and over half the plan participants reinsured have yet to reach retirement.

“We are happy to partner with Rothesay on another innovative Pension Risk Transfer transaction that helps to secure the retirement benefits of Uniq’s members,” said Amy Kessler, senior vice president and head of Prudential’s Longevity Reinsurance business.

“Rothesay Life is pleased to continue its partnership with Prudential,” said Addy Loudiadis, chief executive officer, Rothesay Life. “This latest transaction demonstrates how we can work together to complete an important transaction.”

Reinsurance contracts are issued by Prudential Retirement Insurance and Annuity Company (PRIAC), Hartford, CT 06103. PRIAC is not a U.K. Financial Services Authority (FSA) authorized insurer and does not conduct business in the United Kingdom or provide direct insurance to any individual or entity therein. Prudential Financial, Inc. of the United States is not affiliated with Prudential plc, which is headquartered in the United Kingdom.

Rothesay Life is an insurance company established in the U.K. as a wholly-owned subsidiary of The Goldman Sachs Group, Inc., a bank holding company and leading global investment banking, securities and investment management firm. Rothesay Life provides annuity and other longevity products to corporate defined benefit pension plans, tailored to meet the specific needs of corporate sponsors, trustees and pension plan members. Rothesay Life is authorized and regulated by the U.K.’s Financial Services Authority.

Prudential Retirement delivers retirement plan solutions for public, private, and non-profit organizations. Services include state-of-the-art record keeping, administrative services, investment management, comprehensive employee investment education and communications, and trustee services. With over 85 years of retirement experience, Prudential Retirement helps meet the needs of nearly 3.6 million participants and annuitants. Prudential Retirement has $229.5 billion in retirement account values as of December 31, 2011.

Prudential Financial, Inc. (NYSE: PRU - News), a financial services leader with approximately $901 billion of assets under management as of December 31, 2011, has operations in the United States, Asia, Europe, and Latin America. Prudential’s diverse and talented employees are committed to helping individual and institutional customers grow and protect their wealth through a variety of products and services, including life insurance, annuities, retirement-related services, mutual funds and investment management. In the U.S., Prudential’s iconic Rock symbol has stood for strength, stability, expertise and innovation for more than a century. For more information, please visit http://www.news.prudential.com/.

0218717-00001-00

See the original post:
Prudential Retirement reinsures retirement benefits through transaction with Rothesay Life

DNA barcoding of parasitic worms: Is it kosher?

Posted on by

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Kendra Snyder
ksnyder@amnh.org
212-496-3419
American Museum of Natural History

When rabbis from the Orthodox Union started finding worms in cans of sardines and capelin eggs, they turned to scientists at the American Museum of Natural History to answer a culturally significant dietary question: could these foods still be considered kosher?

Using a technique called "DNA barcoding" at the Museum's Sackler Institute for Comparative Genomics, researchers identified the species and life cycles of the parasitic worms to determine whether the food's preparation violated Jewish dietary laws. The results, which were recently published online in the Journal of Parasitology, show that although the food contains a handful of species of roundworms, it is kosher.

"About 75 percent of all pre-packaged food has a kosher certification," said Mark Siddall, a curator in the Museum's Division of Invertebrate Zoology. "Many people, not just those in the Jewish community, look for this certification as a symbol of quality assurance in food preparation. If you're a food provider and you lose that certification, you're going to take a large hit."

The study began last March, when rabbinical experts from the Orthodox Union, the largest organization that certifies food products for the Jewish community, brought a variety of kosher-certified sardines and capelin eggs to the Museum. Their concern: the presence of the worms might be a sign that intestinal contents were allowed to mix with sardine meat or preserved capelin eggs during food preparation. If that were the case, kosher certification would be compromised.

The key to determining whether the canned food was improperly handled is in the worms' life cycles, Siddall said. "Some species of worms live in the muscles of fish when they're in the larval stage," he said. "Other species live in the fish's intestines when they're adults. We already know the life cycles for these parasites, so all we have to do is figure out what species were present in the canned food."

To do this, researchers used genetic barcoding, a technology based on a relatively short region of a gene in the mitochondrion, an energy-producing structure located outside of the cell's nucleus, that allows researchers to efficiently identify the species from which a piece of meat?or even a leather handbag?came from.

Work by Museum scientists has long included and promoted this technique, which has identified the presence of endangered whales in Asian markets, documented fraud in the labeling of tuna, and determined the species of animals on sale in African bushmeat markets. In this case, the scientists identified a handful of different nematode species, none of which are known to live in the guts of fish during their lifecycles?therefore, there's no evidence of intestinal worms co-mingling with the fish meat or eggs.

As a result, the Orthodox Union issued a decision that the food remains kosher.

"To our knowledge, this is the first application of DNA barcoding to an obviously cultural concern," said Sebastian Kvist, one of the paper's authors and a student in the Museum's Richard Gilder Graduate School. "This paper really exemplifies what science is all about?helping people."

###

Other authors include Anna Phillips, from the University of Connecticut, and Alejandro Oceguera-Figuero, from the National Autonomous University of Mexico.

Funding for the Museum's DNA Barcoding Initiative is provided by the Alfred P. Sloan Foundation and the Richard Lounsbery Foundation.

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

See the original post here:
DNA barcoding of parasitic worms: Is it kosher?

Posted in DNA

Industry-Standard Covaris DNA Shearing Performance for Every Laboratory – Large or Small

Posted on by

WOBURN, Mass., Feb. 14, 2012 /PRNewswire/ -- The M220 Ultrasonicator is the newest DNA shearing system from Covaris.

The M220 is designed for Next-Gen sequencing applications. Using highly controlled AFA™ (Adaptive Focused Acoustics) technology, the M220 reproducibly shears DNA into random fragments ranging from 100bp to 1.5kb.

Compact, cost effective, and easy-to-use, the M220 is the ideal shearing system for MiSeq™ and PGM™ users. The M220 includes integrated cooling, eliminating the extra cost and space required for an external chiller, as well as reducing startup time to just 10 minutes. Using Covaris' microTUBE and miniTUBE consumables and lab-proven protocols, the M220 provides the high quality shearing results researchers have come to expect from Covaris.

The M220 provides the same performance benefits as the market leading S-series and E-series systems from Covaris including, precise energy control for user-selectable DNA fragment lengths, an isothermal process eliminating heat-induced molecular damage, closed vessels for highest sample recovery, and a non-contact process that eliminates cross contamination and clean-up. The M220 was recently released at SLAS and will be presented with performance data at AGBT 2012.

Covaris offers a complete range of DNA shearing products for all Next-Gen sequencing needs. For more information about the M220 Ultrasonicator please visit http://www.covarisinc.com.

About Covaris, Inc.

Covaris, Inc. provides advanced sample preparation systems for life and analytical science. Our sample prep technologies support a wide variety of applications including Next-Generation DNA sequencing, ChIP, proteomics, and compound management. Our patented Adaptive Focused Acoustic (AFA) technology enables a high energy density to bring unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples.

Read this article:
Industry-Standard Covaris DNA Shearing Performance for Every Laboratory - Large or Small

Posted in DNA